JP5851493B2 - 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 - Google Patents
原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 Download PDFInfo
- Publication number
- JP5851493B2 JP5851493B2 JP2013512927A JP2013512927A JP5851493B2 JP 5851493 B2 JP5851493 B2 JP 5851493B2 JP 2013512927 A JP2013512927 A JP 2013512927A JP 2013512927 A JP2013512927 A JP 2013512927A JP 5851493 B2 JP5851493 B2 JP 5851493B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyrrolidine
- mmol
- formula
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002146 bilateral effect Effects 0.000 title description 9
- 201000009395 primary hyperaldosteronism Diseases 0.000 title description 8
- 208000016998 Conn syndrome Diseases 0.000 title description 7
- 208000013846 primary aldosteronism Diseases 0.000 title description 7
- 238000003748 differential diagnosis Methods 0.000 title description 4
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 42
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 39
- 239000000700 radioactive tracer Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- -1 cyclic crown ether compound Chemical class 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 21
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 description 20
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000001919 adrenal effect Effects 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 238000002600 positron emission tomography Methods 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 210000004100 adrenal gland Anatomy 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 208000009888 Adrenocortical Adenoma Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 5
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 description 5
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- GZFAVYWCPSMLCM-UHFFFAOYSA-N (6-methoxynaphthalen-2-yl)boronic acid Chemical compound C1=C(B(O)O)C=CC2=CC(OC)=CC=C21 GZFAVYWCPSMLCM-UHFFFAOYSA-N 0.000 description 4
- XABUXSYPUWVAIO-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)oxyethanol Chemical compound OCCOC1=CN=CC(Br)=C1 XABUXSYPUWVAIO-UHFFFAOYSA-N 0.000 description 4
- QFFZZCVYMPWGJA-UHFFFAOYSA-N 2-[5-(6-methoxynaphthalen-2-yl)pyridin-3-yl]oxyethanol Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C1=CN=CC(OCCO)=C1 QFFZZCVYMPWGJA-UHFFFAOYSA-N 0.000 description 4
- HHZYOGKVEURYRF-UHFFFAOYSA-N 3-bromo-5-(2-fluoroethoxy)pyridine Chemical compound FCCOC1=CN=CC(Br)=C1 HHZYOGKVEURYRF-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- VNYBIBSZZDAEOK-UHFFFAOYSA-N 5-bromopyridin-3-ol Chemical compound OC1=CN=CC(Br)=C1 VNYBIBSZZDAEOK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- OGFAWWOEOUVLSM-UHFFFAOYSA-N 2-bromo-6-(2-fluoroethoxy)naphthalene Chemical compound C1=C(Br)C=CC2=CC(OCCF)=CC=C21 OGFAWWOEOUVLSM-UHFFFAOYSA-N 0.000 description 3
- XNRDLSNSMTUXBV-UHFFFAOYSA-N 2-fluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCF)C=C1 XNRDLSNSMTUXBV-UHFFFAOYSA-N 0.000 description 3
- KXVUKFAHJOQDQS-UHFFFAOYSA-N 3-(2-bromoethoxy)-5-(6-methoxynaphthalen-2-yl)pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C1=CN=CC(OCCBr)=C1 KXVUKFAHJOQDQS-UHFFFAOYSA-N 0.000 description 3
- XZUSIAMUILXWHO-UHFFFAOYSA-N 3-(2-fluoroethoxy)-5-(6-methoxynaphthalen-2-yl)pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C1=CN=CC(OCCF)=C1 XZUSIAMUILXWHO-UHFFFAOYSA-N 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000014594 aldosterone-producing adenoma with seizures and neurological abnormalities Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- MNXGEICAWBHURG-UHFFFAOYSA-N 3-[6-(2-fluoroethoxy)naphthalen-2-yl]-4-methylpyridine Chemical compound CC1=CC=NC=C1C1=CC=C(C=C(OCCF)C=C2)C2=C1 MNXGEICAWBHURG-UHFFFAOYSA-N 0.000 description 2
- GSQZOLXWFQQJHJ-UHFFFAOYSA-N 3-bromo-4-methylpyridine Chemical compound CC1=CC=NC=C1Br GSQZOLXWFQQJHJ-UHFFFAOYSA-N 0.000 description 2
- YLDFTMJPQJXGSS-UHFFFAOYSA-N 6-bromo-2-naphthol Chemical compound C1=C(Br)C=CC2=CC(O)=CC=C21 YLDFTMJPQJXGSS-UHFFFAOYSA-N 0.000 description 2
- 0 C*(C(*)=CN(C)C)=N Chemical compound C*(C(*)=CN(C)C)=N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002739 cryptand Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 206010001361 Adrenal haemorrhage Diseases 0.000 description 1
- 206010053235 Adrenal mass Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- BROAMUNQJDPCMJ-XETXAFAXSA-N CCC([C@@H](C)OC)/C=N\C(C)=C Chemical compound CCC([C@@H](C)OC)/C=N\C(C)=C BROAMUNQJDPCMJ-XETXAFAXSA-N 0.000 description 1
- SUMNOUVEONJYQD-VGXONPELSA-N C[C@]12[C@]3(C)NCC(COC)[C@@H]1[C@@H]23 Chemical compound C[C@]12[C@]3(C)NCC(COC)[C@@H]1[C@@H]23 SUMNOUVEONJYQD-VGXONPELSA-N 0.000 description 1
- XJMBEJZEINZSJM-UHFFFAOYSA-N Cc1ccncc1-c1ccc(C=C(CC2=C)OCCF)c2c1 Chemical compound Cc1ccncc1-c1ccc(C=C(CC2=C)OCCF)c2c1 XJMBEJZEINZSJM-UHFFFAOYSA-N 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BTIYIPHIJWQASU-UHFFFAOYSA-N [6-(2-fluoroethoxy)naphthalen-2-yl]boronic acid Chemical compound C1=C(OCCF)C=CC2=CC(B(O)O)=CC=C21 BTIYIPHIJWQASU-UHFFFAOYSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10164663A EP2394668A1 (en) | 2010-06-01 | 2010-06-01 | PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
| EP10164663.6 | 2010-06-01 | ||
| PCT/EP2011/059135 WO2011151411A1 (en) | 2010-06-01 | 2011-06-01 | Pet radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534911A JP2013534911A (ja) | 2013-09-09 |
| JP2013534911A5 JP2013534911A5 (enExample) | 2014-09-04 |
| JP5851493B2 true JP5851493B2 (ja) | 2016-02-03 |
Family
ID=42668720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512927A Expired - Fee Related JP5851493B2 (ja) | 2010-06-01 | 2011-06-01 | 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130089502A1 (enExample) |
| EP (2) | EP2394668A1 (enExample) |
| JP (1) | JP5851493B2 (enExample) |
| WO (1) | WO2011151411A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861071B1 (en) * | 2012-04-04 | 2017-03-15 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
| JP6048958B2 (ja) | 2012-12-27 | 2016-12-21 | 日本メジフィジックス株式会社 | 副腎疾患の画像診断剤 |
| JP2015193545A (ja) * | 2014-03-31 | 2015-11-05 | 国立大学法人京都大学 | ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬 |
| EP3162802B1 (en) | 2014-06-26 | 2020-08-19 | Nihon Medi-Physics Co., Ltd. | 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same |
| CN109310787A (zh) | 2016-06-10 | 2019-02-05 | 日本医事物理股份有限公司 | 心脏病的非侵入性影像诊断剂 |
| EP3357910A1 (en) | 2017-02-02 | 2018-08-08 | Julius-Maximilians-Universität Würzburg | Compound for in vivo diagnosis of a dysfunction of adrenal glands |
| ES2942768T3 (es) | 2017-12-28 | 2023-06-06 | Nihon Mediphysics Co Ltd | Compuesto derivado de 2-[5-(imidazol-1-ilmetil)piridina-3-il]benzimidazol y medicamento que incluye el mismo |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9271963B2 (en) * | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| BRPI0711481A8 (pt) * | 2006-05-02 | 2017-11-28 | Univ Michigan Regents | derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens |
| WO2011061168A1 (en) * | 2009-11-17 | 2011-05-26 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
-
2010
- 2010-06-01 EP EP10164663A patent/EP2394668A1/en not_active Ceased
-
2011
- 2011-06-01 JP JP2013512927A patent/JP5851493B2/ja not_active Expired - Fee Related
- 2011-06-01 WO PCT/EP2011/059135 patent/WO2011151411A1/en not_active Ceased
- 2011-06-01 US US13/700,767 patent/US20130089502A1/en not_active Abandoned
- 2011-06-01 EP EP11723066.4A patent/EP2575899A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2394668A1 (en) | 2011-12-14 |
| EP2575899A1 (en) | 2013-04-10 |
| US20130089502A1 (en) | 2013-04-11 |
| JP2013534911A (ja) | 2013-09-09 |
| WO2011151411A1 (en) | 2011-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5851493B2 (ja) | 原発性高アルドステロン症の両側性状態と片側性状態との鑑別診断のためのｐｅｔ放射性医薬 | |
| NO20170638A1 (no) | Kontrastmidler for myokardial perfusjonsbilleddannelse | |
| EA018655B1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| JPWO2013042668A1 (ja) | 放射性フッ素標識化合物 | |
| CN112175025B (zh) | 一种含苯环的葡萄糖衍生物及其应用 | |
| JP7036802B2 (ja) | Ｐｅｔ放射性トレーサとしての［１８ｆ］で標識された乳酸誘導体 | |
| JP2023184564A (ja) | 新規化合物 | |
| Garg et al. | 4-11C-methoxy N-(2-diethylaminoethyl) benzamide: a novel probe to selectively target melanoma | |
| WO2020103392A1 (zh) | 一种以7-脱氮腺嘌呤碱基为母核的18f-pet/ct示踪剂及其制备方法 | |
| CA2384879C (en) | Nitroimidazole derivative and diagnostic imaging agent containing the same | |
| JP6048958B2 (ja) | 副腎疾患の画像診断剤 | |
| EP2900278B1 (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
| CN102603647B (zh) | 18/19f-酯类硝基咪唑化合物及其制备方法和作为乏氧组织显像剂的用途 | |
| CA3106903A1 (en) | Fatty acid derivative labeled with positron-emitting radionuclide | |
| WO2016097339A1 (en) | Labelled coumarin derivatives | |
| KR20220128998A (ko) | 양전자 방출 핵종으로 표지된 지방산 유도체 | |
| JP7664650B2 (ja) | グアノシン誘導体及びその製造法 | |
| JP6218366B2 (ja) | Ｈ３受容体の放射性標識リガンド | |
| Park et al. | Synthesis and Evaluation of F‐18 Labeled Pyrido [3, 2‐B] pyrazine Derivative as a Potential Imaging Agent for Non‐Small‐Cell Lung Cancer | |
| CN109438265B (zh) | 一种与棕色脂肪组织具有亲和力的化合物及其制备方法和应用 | |
| JP2015193545A (ja) | ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬 | |
| CN118324760A (zh) | 一种雌激素受体α靶向PET分子探针及其应用 | |
| CN119080714A (zh) | 一种偶氮苯磺酸酯化合物及其制备方法和应用、放射性探针的制备方法 | |
| WO2014126071A1 (ja) | 芳香族アミノ酸誘導体およびそれを用いるｐｅｔプローブ | |
| WO2016097355A1 (en) | Labelled oxazolidinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140716 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150724 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151102 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5851493 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |